New light was shed on the use of TACE and SIRT in the treatment of hepatocellular carcinoma (HCC) by data from clinical trials presented at the International Liver Congress 2013 in Amsterdam, the Netherlands.
New data from two clinical trials presented at the International Liver Congress 2013 demonstrated substantial improvements in the detection of both HCC and cholangiocarcinoma using diagnostic urine tests.
Combining cetuximab (Erbitux) with standard therapy improved the resectability of previously inoperable liver metastases of colorectal cancer.
Monitoring the hepatic function of unresectable liver cancer patients provides vital information that could guide more customized treatment plans and reduce risks of liver injury.
Plant-based drugs primarily used in the treatment of heart failure and arrhythmias have now been found to exert anticancer effects.
Vitamin E from diet or supplements may reduce the risk of developing liver cancer.
Overall US cancer death rates have continued to decline since the early 1990s, but excess weight and lack of sufficient activity contribute to the increased incidence of many cancers.
Pioglitazone, rosiglitazone linked to lower liver cancer risk; rosiglitazone tied to lower CRC risk.
Sorafenib, sunitinib, and pazopanib have been found to carry a heightened risk of fatal complications, but the incidence remains low overall.
Mutations found in about a quarter of cholangiocarcinomas of intrahepatic origin.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|